Oxford Capital and Finance Wales have invested £3.5m in BioMonde, a Welsh wound care company that specialises in larval debridement therapy (LBT), also known as maggot therapy.
Fund has raised €1bn of its €1.1bn target and plans to hold a final close in Q1 2020
GP will take a minority stake, with the Reisenthel family as majority shareholders
Horizon expects to merge the two IT services providers to create a business with 300 developers
EQT deploys capital from its EQT VIII fund, which hit its €10.75bn hard-cap in 2018